While cHL demonstrates remarkable responsiveness to checkpoint inhibition, owing primarily to its characteristic amplification of PD-L1 and PD-L2, other malignancies such as NHL, AML, and MM exhibit more heterogeneous and often limited responses. The gene discussed is PDCD1LG2; the disease is Miyoshi myopathy.